Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Long-Term Debt Issuances (2020 - 2024)

ImmunityBio (IBRX) has disclosed Long-Term Debt Issuances for 5 consecutive years, with -$97.0 million as the latest value for Q4 2024.

  • Quarterly Long-Term Debt Issuances fell 137.48% to -$97.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$97.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $258.7 million for FY2023, 48.57% up from the prior year.
  • Long-Term Debt Issuances for Q4 2024 was -$97.0 million at ImmunityBio, down from $97.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $298.5 million in Q4 2021, with the low at -$97.0 million in Q4 2024.
  • Average Long-Term Debt Issuances over 5 years is $96.1 million, with a median of $63.7 million recorded in 2020.
  • The sharpest move saw Long-Term Debt Issuances soared 420.0% in 2023, then tumbled 137.48% in 2024.
  • Over 5 years, Long-Term Debt Issuances stood at $63.7 million in 2020, then surged by 368.6% to $298.5 million in 2021, then crashed by 83.33% to $49.8 million in 2022, then skyrocketed by 420.0% to $258.7 million in 2023, then crashed by 137.48% to -$97.0 million in 2024.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at -$97.0 million, $97.0 million, and $258.7 million for Q4 2024, Q2 2024, and Q4 2023 respectively.